Life Biosciences’ lead candidate, ER-100 (AAV2-OSK), is in Phase 1/2A clinical trials for optic neuropathies. This is the first-ever epigenetic restoration candidate approved for clinical trials, and if successful, treatment with ER-100 would be the first time cells have been rejuvenated in humans.1,2
Optic neuropathies are a set of serious conditions that cause damage to the retinal ganglion cells (RGCs) of the eye, which are the neuronal cells responsible for transmitting visual signals to the brain. RGCs can be damaged by a range of age-related diseases, collectively termed optic neuropathies. One such serious disease is open-angle glaucoma (OAG).

OAG involves damage to the optic nerve, often due to increased pressure inside the eye. Vision loss typically begins with subtle changes in peripheral (side) vision and progresses slowly over time. Because early stages often have no noticeable symptoms, many people are unaware they have OAG until significant vision loss has occurred. Even for those that catch OAG early, unfortunately, the disease can progress even with the best available treatments.
Diseases like glaucoma cause tremendous burden on patients, caregivers, healthcare systems, and society at large, both through the direct impact of vision impairment/blindness, and through the many consequences associated with vision impairment, including increased risk of institutionalization, higher incidence of falls, and increased social isolation leading to depression and dementia.
Addressing diseases like glaucoma would bring enormous benefit to society…and especially to the patients who suffer from them.
